Immutep : Global Webcast Slides for New Efti Clinical Data in 1st Line HNSCC

TACTI-003 Topline Data Update for Patients with Any PD-L1 Expression (Cohort A) & Negative PD-L1 Expression (Cohort B)

in 1L HNSCC and Overview of TACTI-004 Pivotal Phase III in 1L NSCLC

Global Webcast Presentation - Thursday, June 27th, at 9AM AEST (Wednesday, June 26th, at 7PM ET)

Unlocking the power of the immune system to fight cancer and autoimmune disease

Forward-Looking Statements

The purpose of the presentation is to provide an update of the business of Immutep Limited ACN 009 237 889 (ASX:IMM; NASDAQ:IMMP). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Immutep and should not be relied upon as an independent source of information. Please refer to the Company's website and/or the Company's filings to the ASX and SEC for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Any forward-looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Immutep's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Immutep's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by Immutep. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

This presentation is authorised for release by the CEO of Immutep Limited.

2

Pioneering LAG-3 Immunotherapy Portfolio

	LAG-3
Antigen-presenting	T Cell
cells (APC)
	MHC
	Class II

Immutep has designed multiple first-in-class

therapeutics targeting either MHC Class II molecules on antigen-presenting cells (APC) or LAG-3 on T-cells to fight cancer & autoimmune disease

Targeting MHC Class II on APCs#

Targeting LAG-3 on T cells

Efti	LAG525*	Anti-LAG-3	GSK'781*	IMP761
Soluble LAG-3	Blocking LAG-3	small molecule	Depleting LAG-3	Agonist LAG-3
fusion protein	antibody		antibody	antibody

Oncology	Oncology	Autoimmune Disease
Immune Stimulation	Immune Stimulation	Immune Suppression

3 # MHC Class II = Major Histocompatibility Complex Class II. * LAG525 (leramilimab) is out-licensed to Novartis. The clinical-stage asset, GSK'781 is being transitioned back to Immutep as the licensing agreement has been terminated with an effective date of 30 May 2024.

Deep LAG-3 Pipeline in Oncology & Autoimmune Diseases

Program

Indication

Preclinical

Phase I

Phase II

Late Stage#

Collaborations

Commercial Rights

ONCOLOGY

AUTOIMMUNE	DISEASE

		1L Non-Small Cell Lung Cancer (NSCLC)		TACTI-004 | Efti + Pembrolizumab + Chemo a
		1L Head & Neck Squamous Cell Carcinoma (HNSCC)
			TACTI-003 | Efti + Pembrolizumab a
		1L NSCLC, 2L HNSCC, PD-X Refractory 2L NSCLC
			TACTI-002 | Efti + Pembrolizumab a
	Eftilagimod Alpha	1L Non-Squamous NSCLC		INSIGHT-003 | Efti + Pembrolizumab + Chemo §
	Soluble LAG-3 Protein	Urothelial Cancer		INSIGHT-005 | Efti + Avelumab §, b
	& MHC Class II agonist
Soft Tissue Sarcoma		EFTISARC-NEO | Efti + Pembro + Radiotherapy §
		HR+/HER2- Metastatic Breast Cancer & TNBC		AIPAC-003 | Efti + Paclitaxel
		Metastatic Breast Cancer & Solid Tumors
			Efti + Paclitaxel and Efti + Pembrolizumab ##
	Anti-LAG-3	Undisclosed
	Small Molecule
	Solid Tumors & Blood Cancer
	LAG525	Triple Negative Breast Cancer
	Anti-LAG-3	Melanoma
	Antibody	Solid Tumors
		Triple Negative Breast Cancer
	IMP731*	Ulcerative Colitis
	Psoriasis
	Depleting LAG-3
	Antibody	Healthy Subjects
	IMP761**
	Agonist LAG-3	Undisclosed
	Antibody

Global Rights

ex-China

Efti China Rights

Global Rights

Global Rights

Global Rights

	Information in pipeline chart current as of June 2024. For EOC's China rights, Immutep may receive undisclosed milestones plus royalties; LAG525 (ieramilimab)- ClinicalTrials.gov (for Novartis' global rights, Immutep may receive milestones plus royalties); Immutep has no control over the trials.
4	§ Investigator Initiated Trials controlled by lead investigator & therefore Immutep has no control over these clinical trials. a In combination with KEYTRUDA®. b In combination with BAVENCIO®. # Late stage refers to active Phase IIb clinical trials or more clinically advanced clinical trials. ## Conducted by EOC
	in China.* IMP731 - The clinical-stage asset GSK'781 is being transitioned back to Immutep as the licensing agreement has been terminated with an effective date of 30 May 2024. ** IMP761 - Phase I study to launch mid-CY2024.

Differentiated Approach in Oncology

Efti has complementary action with immune checkpoint inhibitors (ICIs) like anti-PD-(L)1 therapy

Activated Dendritic Cell

Innate		Adaptive	Anti-PD-1
Immunity		Immunity	antibody
NK	CXCL10	CD8+
Cell		T Cell	PD-1
	APC	Efti	T Cell
Monocyte	IFN-ƴ	CD4+
T Cell

Efti's unique activation of antigen-presenting cells (e.g. dendritic cells, monocytes) engages the adaptive and innate immune system, which complements anti-PD-(L)1 therapy to fight cancer

• Efficacy across "hot", "tepid", "cold" tumours in patients with high, low, negative PD-L1 expression
• Additionally, efti in combination with anti-PD-(L)1 has a favourable safety profile

5

Clinical Trials Target Large Addressable Markets

Non-Small Cell Lung Cancer (NSCLC)	HR+/HER2-/TNBC Breast Cancer
drug market estimated at	Head & Neck Cancer
drug market estimated at
drug market estimated at

US$ 24 billion	US$ 12 billion	US$ 3 billion

*Efti has FDA Fast Track designation in 1L NSCLC and 1L HNSCC

6 Market size estimates are based on intelligence data extracted from GlobalData in June 2024 (estimations 2024 for 8MM: FR, DE, IT, JP, ES, UK, US, China), and Nature Reviews Drug Discovery 22, 264-265 (23 Jan 2023) doi: https://doi.org/10.1038/d41573-023-00017-9

TACTI-003

First Line Head & Neck Squamous Cell Carcinoma (1L HNSCC)

Head and Neck Squamous Cell Carcinoma

Overview:

• Head and neck squamous cell carcinoma (HNSCC) encompasses a spectrum of heterogeneous diseases originating in the oral cavity, pharynx, and larynx
• HNSCC is a complex disease involving distinct anatomical sites and with varying etiological factors including smoking, alcohol consumption and infection with Human Papilloma Virus (HPV)

Epidemiology:

• More than 890,000 HNSCC diagnoses and 450,000 deaths per annum worldwide1
• Up to ~100,000 estimated to develop metastatic disease in 8MM countries2
• 5-yearsurvival for metastatic HNSCC is 39.3%3 and varies depending on the anatomical site of cancer origin

TACTI-003 included cancers that originate from the areas delineated by red boxes

Image: © 2012 T. Winslow LLC (US govt has certain rights); (1) Johnson, D.E., Burtness, B., Leemans, C.R. et al. Head and neck squamous cell carcinoma. Nat Rev Dis Primers 6, 92 (2020). https://doi.org/10.1038/s41572-020-00224-3. (2) Extracted from GlobalData in June 2024, 8 Major

8 Markets (8MM): US, China, Japan, France, Germany, Italy, Spain, UK. (3) Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma. Barsouk et. al. Med Sci (Basel). 2023 Jun; 11(2): 42.

Treatment Landscape in 1L HNSCC

High unmet need:

• Overall Survival in first line HNSCC is ~12 months

PD-L1 expression:

• PD-L1expression as measured by Combined Proportion Score (CPS) is an FDA approved predictive biomarker in 1L HNSCC for anti-PD-1 therapy
• Patients are grouped by high (CPS ≥20), low (CPS 1-19), and negative (CPS <1) PD-L1 expression1. Generally, high PD-L1 expressors respond best, low respond sub-optimally, and negative have negligible responses to anti-PD-1 therapies.
• Currently, there are no effective chemotherapy-free treatments for patients with negative PD-L1 expression

High unmet medical need for well tolerated and

efficacious treatment options

Recurrent, unresectable, or metastatic disease not amenable to curative RT or surgery

PD-L1 positive tumor	PD-L1 negative tumor
CPS >1 / CPS >20	CPS <1
Pembrolizumab /	Pembrolizumab	Cetuximab /
doublet chemo	mono	doublet chemo

Further Lines of Therapies

Different chemotherapy alone or in combination (platinum, taxane, methotrexate,

cetuximab…) or anti-PD-1 if not received before

Simplified based on NCCN Guidelines Head and Neck Cancers and EHNS-ESMO-ESTRO Clinical Practice Guidelines

9 The Food and Drug Administration (FDA) approved pembrolizumab in combination with ChT as first-line treatment regardless of PD-L1 expression and pembrolizumab alone for patients with PD-L1-expressing tumours (CPS >1). In contrast, the European Medicines Agency (EMA) has approved pembrolizumab with or without ChT only for patients with a CPS >1. Source: DOI:https://doi.org/10.1016/j.annonc.2020.07.011

TACTI-003 /KEYNOTE-PNC-34 Trial Overview

Efti + anti-PD-1 therapy has FDA Fast Track designation in recurrent or metastatic 1L HNSCC

Cohort A

Randomization

PD-L1 CPS >1

Pembrolizumab + Efti

(i.v. 400 mg q6w; s.c 30mg q2w)

N=138

1:1

Pembrolizumab Monotherapy

(i.v. 400 mg q6w)

ORR, PFS, OS, PK,

biomarker, safety and tolerability

Cohort B

PD-L1 CPS <1

N=33

Pembrolizumab + Efti

(i.v. 400 mg q6w; s.c 30mg q2w)

• Randomized, multicenter Phase IIb trial evaluating efti in combination with pembrolizumab (KEYTRUDA®) in first line recurrent or metastatic head and neck squamous cell carcinoma (1L HNSCC). A total of 171 patients enrolled in 29 clinical sites across nine countries (US, UK, ES, UA, AU, RO, UA, DK, DE):

1. Cohort A (N=138) - Patients with any PD-L1 expression (CPS >1) randomized 1:1 evaluating efti + KEYTRUDA® versus KEYTRUDA monotherapy

• 1. Cohort B (N=33) - Patients with negative PD-L1 expression (CPS <1), which could not be randomized as KEYTRUDA monotherapy is not approved in CPS <1
• Primary endpoint is Overall Response Rate (ORR) among evaluable patients (>= 1 post baseline CT), according to RECIST1.1
• Secondary endpoints include Overall Survival and Progression-Free Survival, ORR (iRECIST), and Disease Control Rate

The Food and Drug Administration (FDA) approved pembrolizumab in combination with ChT as first-line treatment regardless of PD-L1 expression and pembrolizumab alone for patients with PD-L1-expressing tumours (CPS >1). In contrast, the European Medicines Agency (EMA) has approved pembrolizumab

10 with or without ChT only for patients with a CPS >1. Source: DOI:https://doi.org/10.1016/j.annonc.2020.07.011. Approval based on KN-048. Immutep conducts this clinical trial and has a clinical trial collaboration and supply agreement with Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the US and Canada).